Novo Nordisk raised its 2026 outlook on 4 November after reporting better-than-expected third-quarter adjusted profit. The company reported adjusted operating profit of DKK 31.72 billion and adjusted quarterly sales of approximately DKK 79.20 billion. Its Wegovy pill generated DKK 5.39 billion in quarterly revenue. Novo now expects full-year adjusted sales and adjusted operating profit growth at constant ExchangeDefinition An exchange is an organised marketplace where buyers and sellers can trade financial assets according to a common set of rules. Examples of assets traded on exc...Read More rates to RangeA market state where price moves between boundaries without a clear sequence of higher highs or lower lows. Waiting is a valid read here.Read More from a decline of 2% to growth of 2%, versus a previously weaker outlook. The company also reported impairment charges that weighed on reported operating profit, so adjusted and reported earnings should not be conflated. Reuters reported that shares initially rose after the announcement.
Novo Nordisk raised its 2026 financial outlook after reporting stronger-than-expected third-quarter adjusted earnings. The Danish pharmaceutical company posted adjusted operating profit of DKK 31.72 billion and sales of approximately DKK 79.20 billion, including DKK 5.39 billion from its Wegovy pill. It now forecasts full-year adjusted sales and operating profit growth of between -2% and +2% at constant exchange rates. Shares initially gained following the announcement, although impairment charges weighed on reported operating profit.
